Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_1
3
60%
Ph not_applicable
2
40%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(4)

Detailed Status

Completed4
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (60.0%)
N/A2 (40.0%)

Trials by Status

enrolling_by_invitation120%
completed480%

Recent Activity

0 active trials
Showing 5 of 5
completednot_applicable

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

NCT04860323
enrolling_by_invitationphase_1

Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART

NCT06908083
completedphase_1

3BNC117 and 10-1074 in ART-treated Individuals

NCT03526848
completednot_applicable

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study

NCT04801758
completedphase_1

3BNC117 and 10-1074 in HIV-infected Individuals

NCT02825797

Clinical Trials (5)

Showing 5 of 5 trials
NCT04860323Not Applicable

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

Completed
NCT06908083Phase 1

Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART

Enrolling By Invitation
NCT03526848Phase 1

3BNC117 and 10-1074 in ART-treated Individuals

Completed
NCT04801758Not Applicable

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study

Completed
NCT02825797Phase 1

3BNC117 and 10-1074 in HIV-infected Individuals

Completed

All 5 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
5